Sesen Bio Files Definitive Proxy Statement and Mails Letter to Stockholders in Connection with Pending Merger with Carisma Therapeutics

19.01.2023 - Sesen Bio, Inc. (Nasdaq: SESN) today announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission in connection with the Company’s pending merger with Carisma Therapeutics Inc. (Carisma), a privately held, ...

Related Keywords

University Of Pennsylvania ,Pennsylvania ,United States ,Wellington ,New Zealand General ,New Zealand ,Philadelphia ,Bradley Radoff ,Michael Klichinsky ,Michael Torok ,Steven Kelly ,Securities Exchange Commission ,Investor Group ,Hogan Lovells ,Drug Administration ,Nasdaq ,Novartis ,Therapeutics Inc ,Sesen Bio Inc ,Carisma Therapeutics Inc ,Sesen Bio Board ,Sesen Bio ,Fellow Stockholder ,Carisma Therapeutics ,Upfront Cash ,Upside Opportunity ,Potential Cash Upsidevia ,Contingent Value Right ,Roche Asset Purchase ,Strategic Alternatives ,Maximize Stockholder Value ,Young Entrepreneur ,Chief Scientific Officer ,Nasdaq Listing Rule ,Sesen Bio Certificate ,Mackenzie Partners ,United States Food ,Private Securities ,Litigation Reform Act ,Nasdaq Stock Market ,Annual Report ,Quarterly Reports ,Securities Act ,Current Report ,Sesen Bio Stock ,